Table 3.

APOE haplotypes effects on neuropathological features measured in autopsies of AD cases and non-AD controls. Odds ratios and p-values are obtained from a logistic or ordinal regression model controlling for confounders and the dosages of the different haplotypes. ε3 is taken as the reference haplotype

	AD			Control
	E2	E4 Anc.	E4 Eur.	E2	E4 Anc.	E4 Eur.
Whole brain weight	0.96	0.91	1.04	1.04	0.74	0.64*
Fresh or fixed weight	1.3	1	1	0.69	0.57	0.26
Cerebral cortex atrophy	1.07	1.11	1.01	0.8	1.16	1.91**
Lobar atrophy	0.73	0.66	1.03	1	12*	1.1
Hippocampus atrophy	1.08	1.17	1.03	1.11	0.99	0.69
White matter rarefaction	0.9	1.11	1.03	0.79	1.34	0.93
Arteriolosclerosis	0.78	0.85	0.97	1.12	1.61	1.91
Atherosclerosis	0.99	1.06	0.93	0.8	1.03	0.81
Microinfarcts	1.52	1.57	1.16	0.58	0.68	0.44
Infarcts	0.56	1.3	1.3	1.1	1.40E–07	0.55
Braak stage for neurofibrillary degeneration	0.78*	1.23*	1.3****	1.33	2.79***	1.19
CERAD score for neuritic plaques	0.74**	1.3**	1.34****	0.73	1.35	1.26
NIA-AA ADNC	0.73	1.17	1.28***	0.81	2.33	1.77*

^*p < 0.05,

^**p < 0.01,

^***p < 0.001,

^****p < 0.0001.